NCT05961202View on ClinicalTrials.gov

The Effects of Hydroxychloroquine in Patients with Inflammatory Cardiomyopathy

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

November 1, 2021

Primary Completion Date

September 1, 2024

Study Completion Date

November 1, 2025

Conditions
Inflammatory CardiomyopathyMyocarditis
Interventions
DRUG

Hydroxychloroquine

Hydroxychloroquine 200mg qd

DRUG

Prednisolone

Prednisolone 20mg qd

Trial Locations (1)

430030

RECRUITING

Tongji Hospital, Wuhan

All Listed Sponsors
collaborator

Wuhan Central Hospital

OTHER

collaborator

Taihe Hospital

OTHER

lead

Tongji Hospital

OTHER